Over the last 10 years, the pharmaceutical industry’s attention has shifted away from the industry stalwart of chemistry and small molecules, to focus on the new biologics gold rush of monoclonal antibodies and recombinant proteins. As a result, the chemical API market for western contract manufacturers as a whole suffered decline and consolidation throughout 2005-2015. Many custom manufacturing organizations (CMOs) shifted focus to higher-value biologics manufacturing, mothballing plants or exiting the business completely. Encouragingly over the last few years, this vogue appears to have subsided, and attention now appears to be back with small molecules therapeutics demonstrated by a growing worldwide demand and several blockbusters launched or pending launch over the past few years and near future.
As many industry experts will acknowledge, quantification of the small molecule API industry is difficult with most reviews or analyses either misleading or lacking sufficient depth to be useful. In this webinar, Cambrex’s marketing intelligence group and fine chemicals industry expert, Jan Ramakers, will use their compiled and individual data to outline and review the pharmaceutical market from the vantage point of chemical molecules and present an overview of the API market. We attempt to present a balanced review of the competitive CMO landscape for small molecule API manufacturing and show how Cambrex is positioned within the CMO market.
Dr. Matthew Moorcroft, VP of Global Marketing, Cambrex
Dr. Jan Ramakers, Director, Jan Ramakers Fine Chemical Consulting Group